Connect with us

Biotechnology

Time for a New Vaccine Production Model? Spotlight on DYAI (NASDAQ: DYIA)

Published

on

India is burning in Covid flames. Brazil is in basically the same shape. It’s likely only a matter of time before much of Africa is in a similar situation.

This is the real reckoning.

In the US and the EU, and “rich Asia”, the story is turning to roses. But that tells the story for far less than half the world in per capita terms.

The reason that’s so problematic is because large populations of unvaccinated masses represent a breeding ground for new variants, many of which will begin before long to fall outside of the efficacy boundaries for the vaccines now protecting us in OECD nations.

The tragedy now underway in India is a reminder. As noted in the Wall Street Journal over the weekend, “India’s surge came after loosening restrictions and public complacency set in, with highly contagious variants now spreading around the globe potentially serving as an accelerant. The outbreak threatens to extend the pandemic itself, driving world-wide numbers to new highs and creating an enormous viral pool that could become a breeding ground for new and potentially dangerous mutations.”

“It is a major point of concern that more troublesome variants can emerge if left unchecked,” said Rakesh Mishra, director of the Centre for Cellular and Molecular Biology in Hyderabad, who works on genome sequencing of Covid-19 samples. “I don’t even want to imagine a more nasty variant.”

This is a key notion facing major vaccine producers such as Pfizer Inc (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), AstraZeneca plc (NASDAQ: AZN), Novavax Inc (NASDAQ: NVAX), and Johnson & Johnson (NYSE: JNJ).

That brings Dyadic International Inc (NASDAQ:DYAI) into focus as a new approach given the transformative Dyadic C1 Protein Technology it holds as a solution that could offer a path to more rapidly and cheaply vaccinating the whole world and massively undermining the virus’s ability to conjure up new pathways to supplanting our resources for protecting human life.

The New Path

Dyadic International Inc (NASDAQ:DYAI) is set to conduct a “Fireside Chat” on Tuesday, May 4, 2021 at 10:00am Eastern Time. The fireside chat will focus on the potential of the transformative Dyadic C1 protein technology in helping meet global health challenges.

The moderated discussion will include the following Key Opinion Leaders: Alain Townsend, Ph.D. – Weatherall Institute – Oxford University, Albert Osterhaus, P.V.M, Ph.D. – Erasmus Medical Centre, Cecil Nick – Parexel (Clinical & Regulatory Support), and Joris Vandeputte – International Alliance for Biological Standardization.

According to DYAI’s recent release, the discussion will include regulatory considerations and advantages of the C1 platform, case studies describing the successful production of high value antigens for both Schmallenburg Virus and Rift Valley Fever Virus in relation to the performance in other production platforms, the efforts being undertaken by Dyadic to address the emerging SARS-CoV-2 variants including Dyadic’s development efforts advancing a SARS-CoV-2 receptor binding domain (RBD) vaccine candidate – DYAI-100 plus the rapid engineering of C1 cell lines to express known and emerging variants, the C1 platform’s potential for developing and manufacturing multi-valent COVID-19 and other subunit vaccines, including a pan-coronavirus vaccine that can protect against most or all variants, and glycoengineering C1-cells to produce mAbs and other antibodies.

As noted by the company, the conversation will be moderated by Dr. David Bramhill, a veteran in the biotechnology industry with extensive experience using a wide array of protein production technologies including E. coli, Saccharomyces cerevisiae, Pichia pastoris, Tetrahymena, Insect SF9 stable cells (not baculovirus), CHO, and HEK293.

The Big Reveal

As this presentation unfolds, it could create a splash among scientific circles because Dyadic International Inc (NASDAQ:DYAI) has something special to offer that will be covered as this process moves forward.

DYAI has developed what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.

The C1 microorganism, technically a fungal body, enables the development and large-scale manufacture of low-cost proteins and has the potential to be further developed into a safe and efficient expression system that may help speed up the development of biologic vaccines and drugs at commercial scales, while lowering production costs and improving performance at the same time.

DYAI’s patented and proprietary C1 gene expression and recombinant protein production platform was selected by ZAPI as a production host of antigens for the Schmallenberg virus (SBV) and Rift Valley Fever virus (RVFV).

Proteins associated with vaccine production are produced through a “vector”. The baculovirus–insect cell expression system is a commonly used vector and has been extensively utilized for the production of many recombinant proteins and commercial vaccines.

However, the SBV antigen from C1 produced 300 times greater yields than the SBV antigen from baculovirus and was more stable.

Additionally, the C1 SBV antigen was shown to be safe and very effective (Full Protection) in protecting cattle and mice from the SBV. Based on these results, additional fully funded animal trials are continuing in 2021 with C1 expressed antigens for SBV and RVFV and to generate additional safety and efficacy data.

If the same results may come to apply to the crisis starting to take root in the developing world, where it will take much longer to vaccinate with current solutions at a price tag no one is likely to assume responsibility for among those who can, then it could be a game changer.

Given where DYAI shares are trading now, it’s likely that none of this potential has yet to be priced into the stock. That could potentially represent a speculative opportunity for interested investors.

DISCLAIMER:  EDM Media LLC (EDM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  EDM is NOT affiliated in any manner with any company mentioned herein.  EDM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  EDM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  EDM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed EDM has been compensated six thousand dollars for news coverage of the current press releases issued by Dyadic International Inc (NASDAQ:DYAI) by a third party.

EDM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and EDM undertakes no obligation to update such statements.

Media Contact:

EDM Media LLC

Email: [email protected]

Office: 800-301-7883

EDM.Media

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://otcprwire.com/time-for-a-new-vaccine-production-model-spotlight-on-dyai-nasdaq-dyia/

Biotechnology

A new way to detect the SARS-CoV-2 Alpha variant in wastewater

Published

on

Researchers from the Antimicrobial Resistance (AMR) interdisciplinary research group at the Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, alongside collaborators from Biobot Analytics, Nanyang Technological University (NTU), and MIT, have successfully developed an innovative, open-source molecular detection method that is able to detect and quantify the B.1.1.7 (Alpha) variant of SARS-CoV-2. The breakthrough paves the way for rapid, inexpensive surveillance of other SARS-CoV-2 variants in wastewater.

As the world continues to battle and contain Covid-19, the recent identification of SARS-CoV-2 variants with higher transmissibility and increased severity has made developing convenient variant tracking methods essential. Currently, identified variants include the B.1.17 (Alpha) variant first identified in the United Kingdom and the B.1.617.2 (Delta) variant first detected in India.

Wastewater surveillance has emerged as a critical public health tool to safely and efficiently track the SARS-CoV-2 pandemic in a non-intrusive manner, providing complementary information that enables health authorities to acquire actionable community-level information. Most recently, viral fragments of SARS-CoV-2 were detected in housing estates in Singapore through a proactive wastewater surveillance program. This information, alongside surveillance testing, allowed Singapore’s Ministry of Health to swiftly respond, isolate, and conduct swab tests as part of precautionary measures.

However, detecting variants through wastewater surveillance is less commonplace due to challenges in existing technology. Next-generation sequencing for wastewater surveillance is time-consuming and expensive. Tests also lack the sensitivity required to detect low variant abundances in dilute and mixed wastewater samples due to inconsistent and/or low sequencing coverage.

The method developed by the researchers is uniquely tailored to address these challenges and expands the utility of wastewater surveillance beyond testing for SARS-CoV-2, toward tracking the spread of SARS-CoV-2 variants of concern.

Wei Lin Lee, research scientist at SMART AMR and first author on the paper adds, “This is especially important in countries battling SARS-CoV-2 variants. Wastewater surveillance will help find out the true proportion and spread of the variants in the local communities. Our method is sensitive enough to detect variants in highly diluted SARS-CoV-2 concentrations typically seen in wastewater samples, and produces reliable results even for samples which contain multiple SARS-CoV-2 lineages.”

Led by Janelle Thompson, NTU associate professor, and Eric Alm, MIT professor and SMART AMR principal investigator, the team’s study, “Quantitative SARS-CoV-2 Alpha variant B.1.1.7 Tracking in Wastewater by Allele-Specific RT-qPCR” has been published in Environmental Science & Technology Letters. The research explains the innovative, open-source molecular detection method based on allele-specific RT-qPCR that detects and quantifies the B.1.1.7 (Alpha) variant. The developed assay, tested and validated in wastewater samples across 19 communities in the United States, is able to reliably detect and quantify low levels of the B.1.1.7 (Alpha) variant with low cross-reactivity, and at variant proportions down to 1 percent in a background of mixed SARS-CoV-2 viruses.

Targeting spike protein mutations that are highly predictive of the B.1.1.7 (Alpha) variant, the method can be implemented using commercially available RT-qPCR protocols. Unlike commercially available products that use proprietary primers and probes for wastewater surveillance, the paper details the open-source method and its development that can be freely used by other organizations and research institutes for their work on wastewater surveillance of SARS-CoV-2 and its variants.

The breakthrough by the research team in Singapore is currently used by Biobot Analytics, an MIT startup and global leader in wastewater epidemiology headquartered in Cambridge, Massachusetts, serving states and localities throughout the United States. Using the method, Biobot Analytics is able to accept and analyze wastewater samples for the B.1.1.7 (Alpha) variant and plans to add additional variants to its analysis as methods are developed. For example, the SMART AMR team is currently developing specific assays that will be able to detect and quantify the B.1.617.2 (Delta) variant, which has recently been identified as a variant of concern by the World Health Organization.

“Using the team’s innovative method, we have been able to monitor the B.1.1.7 (Alpha) variant in local populations in the U.S. — empowering leaders with information about Covid-19 trends in their communities and allowing them to make considered recommendations and changes to control measures,” says Mariana Matus PhD ’18, Biobot Analytics CEO and co-founder.

“This method can be rapidly adapted to detect new variants of concern beyond B.1.1.7,” adds MIT’s Alm. “Our partnership with Biobot Analytics has translated our research into real-world impact beyond the shores of Singapore and aid in the detection of Covid-19 and its variants, serving as an early warning system and guidance for policymakers as they trace infection clusters and consider suitable public health measures.”

The research is carried out by SMART and supported by the National Research Foundation (NRF) Singapore under its Campus for Research Excellence And Technological Enterprise (CREATE) program.

SMART was established by MIT in partnership with the National Research Foundation of Singapore (NRF) in 2007. SMART is the first entity in CREATE developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore, undertaking cutting-edge research projects in areas of interest to both Singapore and MIT. SMART currently comprises an Innovation Center and five IRGs: AMR, Critical Analytics for Manufacturing Personalized-Medicine, Disruptive and Sustainable Technologies for Agricultural Precision, Future Urban Mobility, and Low Energy Electronic Systems.

The AMR interdisciplinary research group is a translational research and entrepreneurship program that tackles the growing threat of antimicrobial resistance. By leveraging talent and convergent technologies across Singapore and MIT, AMR aims to develop multiple innovative and disruptive approaches to identify, respond to, and treat drug-resistant microbial infections. Through strong scientific and clinical collaborations, its goal is to provide transformative, holistic solutions for Singapore and the world.

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://news.mit.edu/2021/new-way-to-detect-sars-cov-2-alpha-variant-in-wastewater-0728

Continue Reading

Biotechnology

A new way to detect the SARS-CoV-2 Alpha variant in wastewater

Published

on

Researchers from the Antimicrobial Resistance (AMR) interdisciplinary research group at the Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, alongside collaborators from Biobot Analytics, Nanyang Technological University (NTU), and MIT, have successfully developed an innovative, open-source molecular detection method that is able to detect and quantify the B.1.1.7 (Alpha) variant of SARS-CoV-2. The breakthrough paves the way for rapid, inexpensive surveillance of other SARS-CoV-2 variants in wastewater.

As the world continues to battle and contain Covid-19, the recent identification of SARS-CoV-2 variants with higher transmissibility and increased severity has made developing convenient variant tracking methods essential. Currently, identified variants include the B.1.17 (Alpha) variant first identified in the United Kingdom and the B.1.617.2 (Delta) variant first detected in India.

Wastewater surveillance has emerged as a critical public health tool to safely and efficiently track the SARS-CoV-2 pandemic in a non-intrusive manner, providing complementary information that enables health authorities to acquire actionable community-level information. Most recently, viral fragments of SARS-CoV-2 were detected in housing estates in Singapore through a proactive wastewater surveillance program. This information, alongside surveillance testing, allowed Singapore’s Ministry of Health to swiftly respond, isolate, and conduct swab tests as part of precautionary measures.

However, detecting variants through wastewater surveillance is less commonplace due to challenges in existing technology. Next-generation sequencing for wastewater surveillance is time-consuming and expensive. Tests also lack the sensitivity required to detect low variant abundances in dilute and mixed wastewater samples due to inconsistent and/or low sequencing coverage.

The method developed by the researchers is uniquely tailored to address these challenges and expands the utility of wastewater surveillance beyond testing for SARS-CoV-2, toward tracking the spread of SARS-CoV-2 variants of concern.

Wei Lin Lee, research scientist at SMART AMR and first author on the paper adds, “This is especially important in countries battling SARS-CoV-2 variants. Wastewater surveillance will help find out the true proportion and spread of the variants in the local communities. Our method is sensitive enough to detect variants in highly diluted SARS-CoV-2 concentrations typically seen in wastewater samples, and produces reliable results even for samples which contain multiple SARS-CoV-2 lineages.”

Led by Janelle Thompson, NTU associate professor, and Eric Alm, MIT professor and SMART AMR principal investigator, the team’s study, “Quantitative SARS-CoV-2 Alpha variant B.1.1.7 Tracking in Wastewater by Allele-Specific RT-qPCR” has been published in Environmental Science & Technology Letters. The research explains the innovative, open-source molecular detection method based on allele-specific RT-qPCR that detects and quantifies the B.1.1.7 (Alpha) variant. The developed assay, tested and validated in wastewater samples across 19 communities in the United States, is able to reliably detect and quantify low levels of the B.1.1.7 (Alpha) variant with low cross-reactivity, and at variant proportions down to 1 percent in a background of mixed SARS-CoV-2 viruses.

Targeting spike protein mutations that are highly predictive of the B.1.1.7 (Alpha) variant, the method can be implemented using commercially available RT-qPCR protocols. Unlike commercially available products that use proprietary primers and probes for wastewater surveillance, the paper details the open-source method and its development that can be freely used by other organizations and research institutes for their work on wastewater surveillance of SARS-CoV-2 and its variants.

The breakthrough by the research team in Singapore is currently used by Biobot Analytics, an MIT startup and global leader in wastewater epidemiology headquartered in Cambridge, Massachusetts, serving states and localities throughout the United States. Using the method, Biobot Analytics is able to accept and analyze wastewater samples for the B.1.1.7 (Alpha) variant and plans to add additional variants to its analysis as methods are developed. For example, the SMART AMR team is currently developing specific assays that will be able to detect and quantify the B.1.617.2 (Delta) variant, which has recently been identified as a variant of concern by the World Health Organization.

“Using the team’s innovative method, we have been able to monitor the B.1.1.7 (Alpha) variant in local populations in the U.S. — empowering leaders with information about Covid-19 trends in their communities and allowing them to make considered recommendations and changes to control measures,” says Mariana Matus PhD ’18, Biobot Analytics CEO and co-founder.

“This method can be rapidly adapted to detect new variants of concern beyond B.1.1.7,” adds MIT’s Alm. “Our partnership with Biobot Analytics has translated our research into real-world impact beyond the shores of Singapore and aid in the detection of Covid-19 and its variants, serving as an early warning system and guidance for policymakers as they trace infection clusters and consider suitable public health measures.”

The research is carried out by SMART and supported by the National Research Foundation (NRF) Singapore under its Campus for Research Excellence And Technological Enterprise (CREATE) program.

SMART was established by MIT in partnership with the National Research Foundation of Singapore (NRF) in 2007. SMART is the first entity in CREATE developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore, undertaking cutting-edge research projects in areas of interest to both Singapore and MIT. SMART currently comprises an Innovation Center and five IRGs: AMR, Critical Analytics for Manufacturing Personalized-Medicine, Disruptive and Sustainable Technologies for Agricultural Precision, Future Urban Mobility, and Low Energy Electronic Systems.

The AMR interdisciplinary research group is a translational research and entrepreneurship program that tackles the growing threat of antimicrobial resistance. By leveraging talent and convergent technologies across Singapore and MIT, AMR aims to develop multiple innovative and disruptive approaches to identify, respond to, and treat drug-resistant microbial infections. Through strong scientific and clinical collaborations, its goal is to provide transformative, holistic solutions for Singapore and the world.

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://news.mit.edu/2021/new-way-to-detect-sars-cov-2-alpha-variant-in-wastewater-0728

Continue Reading

Biotechnology

In an increasingly hot biotech market, protecting IP is key

Published

on

After a record year for biotech investment in 2020 — during which the industry saw $28.5 billion invested across 1,073 deals — the market for new innovations remains strong. What’s more, these innovations are increasingly coming to market by way of early-stage startups and/or their scientific founders from academia.

In 2018, for instance, U.S. campuses conducted $79 billion worth of sponsored research, much of it thanks to the federal government. That number spiked amid the pandemic and could increase even more if President Biden’s infrastructure plan, which includes $180 billion to enhance R&D efforts, passes.

Since 1996, 14,000 startups have licensed technology out of those universities, and 67% of licenses were taken by startups or small companies. Meanwhile, the median step-up from seed to Series A is now 2x — higher than all other stages, suggesting that biotech startups are continuing to attract investment at earlier stages.

When it comes to protecting IP, early and consistent communication with investors, tech transfer offices and advisers can make all the difference.

For biotech startups and their founders, these headwinds signal immense promise. But initial funding is only one part of a long journey that (ideally) ends with bringing a product to market. Along the way, founders will need to procure additional investments, develop strategic partnerships and stave off competition. All of which starts by protecting the fundamental asset of any biotech company: its intellectual property.

Here are three key considerations for startups and founders as they get started.

Start with an option agreement

Most early-stage biotechnology starts in a university lab. Then, a disclosure is made with the university’s tech transfer office and a patent is filed with the hopes that the product can be taken out into the market (by, for instance, a new startup). More often than not, the vehicle to do this is a licensing agreement.

A licensing agreement is important because it shows investors the company has exclusive access to the technology in question. This in turn allows them to attract the investments required to truly grow the company: hire a team, build strategic partnerships and conduct additional studies.

But that doesn’t mean jumping right to a full-blown licensing agreement is the best way to start. An option agreement is often the better move.

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://techcrunch.com/2021/07/16/in-an-increasingly-hot-biotech-market-protecting-ip-is-key/

Continue Reading

Biotechnology

Cutting out carbon emitters with bioengineering at XTC Global Finals on July 22

Published

on

Bioengineering may soon provide compelling, low-carbon alternatives in industries where even the best methods produce significant emissions. Utilizing natural and engineered biological process has led to low-carbon textiles from Algiknit, cell-cultured premium meats from Orbillion, and fuels captured from waste emissions via LanzaTech — and leaders from those companies will be joining us on stage for the Extreme Tech Challenge Global Finals on July 22.

We’re co-hosting the event, with panels like this one all day and a pitch-off that will feature a number of innovative startups with a sustainability angle.

I’ll be moderating a panel on using bioengineering to create change directly in industries with large carbon footprints: textiles, meat production, and manufacturing.

Algiknit is a startup that is sourcing raw material for fabric from kelp, which is an eco-friendly alternative to textile crop monocultures and artificial materials like acrylic. CEO Aaron Nesser will speak to the challenge of breaking into this established industry and overcoming preconceived notions of what an algae-derived fabric might be like (spoiler: it’s like any other fabric).

Orbillion Bio is one of the new crop of alternative protein companies offering cell-cultured meats (just don’t call them “lab” or “vat” grown) to offset the incredibly wasteful livestock industry. But it’s more than just growing a steak — there are regulatory and market barriers aplenty that CEO Patricia Bubner can speak to as well as the technical challenge.

LanzaTech works with factories to capture emissions as they’re emitted, collecting the useful particles that would otherwise clutter the atmosphere and repurposing them in the form of premium fuels. This is a delicate and complex process that needs to be a partnership, not just a retrofitting operation, so CEO Jennifer Holmgren will speak to their approach convincing the industry to work with them at the ground floor.

It should be a very interesting conversation, so tune in on July 22 to hear these and other industry leaders focused on sustainability discuss how innovation at the startup level can contribute to the fight against climate change. Plus it’s free!

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://techcrunch.com/2021/07/12/cutting-out-carbon-emitters-with-bioengineering-at-xtc-global-finals-on-july-22/

Continue Reading
Aviation5 days ago

Legendary F-14 Pilot Dale ‘Snort’ Snodgrass Dies In A Tragic Plane Crash

watch-live-russias-pirs-module-set-to-depart-space-station-today.jpg
Aerospace4 days ago

Watch live: Russia’s Pirs module set to depart space station today

Esports4 days ago

Genshin Impact Sacred Sakura Cleansing Ritual Quest Guide

Esports4 days ago

Genshin Impact Sacrificial Offering: How to Complete

Esports3 days ago

League of Legends Wild Rift Patch 2.4 Release Date

Esports4 days ago

Best bot lane Pokémon on Pokémon UNITE

Esports5 days ago

Where to Find Rivercress Stem in New World

Energy4 days ago

NexGen Announces Commencement of 2021 Field and Regional Exploration Drilling Programs at the Rook I Property

Crowdfunding4 days ago

Digital Asset Firm Kraken Releases Report on Benefits of Centralized Finance Platforms Amid DeFi Boom

AR/VR20 hours ago

Review: Winds & Leaves

Esports5 days ago

Pokémon UNITE Crustle Build

Blockchain4 days ago

Ethereum 2.0 Exceeds 200K Validators, Has 6.6 Million ETH in Staking

Esports5 days ago

PUBG Mobile Global Championship (PMGC) 2021 unveiled with $6 million prize pool

Energy4 days ago

Nowa umowa partnerska Shanghai Electric zawarta podczas WAIC 2021 doprowadzi do rozwoju i przemiany wielu branż dzięki transformacji cyfrowej

Blockchain3 days ago

Ethereum Inventor Debuts As An Actor? Joins Mila Kunis In NFT-Based Show

Esports5 days ago

How to Beat Alastor the Vigilant in New World

Esports3 days ago

TFT Set 5.5 11.15 B-patch nerfs Hecarim, Lucian, and Irelia

Esports5 days ago

Best Wigglytuff build in Pokémon UNITE

Fintech3 days ago

Finding the right balance with hybrid client experiences

Energy3 days ago

SOL: Sasol Limited – Production And Sales Metrics And Financial Results For The Year Ended 30 June 2021

Trending